Checked.be
Active
BE 0779.459.435Private limited company
MC4 THERAPY
François Delcoignestraat 45 ·1081 Koekelberg, Belgium· 4 yrs active
Conclusion
The computed 12-month bankruptcy probability of MC4 THERAPY is 4.4% (elevated). The 2025 annual accounts show equity of €12k and a net result of €4k. Equity is shrinking by ~4.9% per year across the filed fiscal years. Its solvency ranks better than 90% of 16012 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 4 annual accounts.
Key figures
| Equity | €12k |
| Net result | €4k |
| Better than sector | 90% |
| Active | 4 yrs |
Financial profile
85
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
100
Profitability
100
Solvency
100
Growth
32
Stability
94
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2021, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
100
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€1k
estimate, not credit advice
Score history
93
2022
93
2023
52
2024
100
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 15.00 (≥ 1.5)
+10
Quick ratio
Quick ratio 15.00 (≥ 1.0)
+5
Leverage
Debt/equity 0.06 (< 1.0)
+10
Profitability
ROE 30% (≥ 10%)
+10
Interest coverage
Interest coverage 140.6× (≥ 3×)
+8
Profit trend
Net profit up YoY
+5
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 20-07-2026 with the NBB · fiscal year 2025 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
volatile
Too volatile to project: the yearly deviation from the trend is ~64% of the level (threshold 35%). We therefore deliberately show no projection line.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 94.7% | 63.4% | |
| Net result | €4k | €62k | |
| Equity | €12k | €132k | |
| Gross operating margin | €8k | €116k | |
| Total assets | €13k | €286k |
€7k
-
22-25
€4k
-
22-25
€6k
-
22-25
€13k
+14.6%
22-25
€12k
+43.9%
22-25
€10k
+138.6%
22-25
€253
-
22-25
€462
-
22-25
€693
-75.3%
22-25
€693
-75.3%
22-25
15.00
+512.1%
22-25
15.00
+512.1%
22-25
94.7%
+25.6%
22-25
0.06
-82.8%
22-25
30.5%
-
22-25
28.9%
-
22-25
140.62
-
22-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - |
| EBITDA | €7k | €-4k | €6k | €15k |
| Net profit | €4k | €-6k | €2k | €11k |
| Cash flow | €6k | €-4k | €4k | €11k |
| Staff costs | - | €253 | - | - |
| Income taxes | €462 | €-36 | €1k | €3k |
| Dividends | - | - | - | - |
| Total assets | €13k | €11k | €21k | €21k |
| Equity | €12k | €9k | €15k | €13k |
| Debt | €693 | €3k | €6k | €8k |
| of which ≤ 1y | €693 | €3k | €6k | €8k |
| of which > 1y | - | - | - | - |
| Working capital | €10k | €4k | €9k | €6k |
| Employees (FTE) | - | - | - | - |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 15.00 | 2.45 | 2.52 | 1.73 |
| Quick ratio | 15.00 | 2.45 | 2.52 | 1.73 |
| Working capital ratio | 74.2% | 35.6% | 42.3% | 28.1% |
| Solvency | 94.7% | 75.4% | 72.2% | 61.3% |
| Debt / equity | 0.06 | 0.33 | 0.39 | 0.63 |
| Long-term debt ratio | - | - | - | - |
| Interest coverage | 140.62 | -90.27 | 98.61 | 413.31 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 28.9% | -55.9% | 11.5% | 51.5% |
| ROE | 30.5% | -74.1% | 16.0% | 84.1% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (21 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €13k | €11k | €21k | €21k |
| Fixed assets | 21/28 | €3k | €5k | €6k | €7k |
| Tangible fixed assets | 22/27 | €3k | €5k | €6k | €7k |
| Current assets | 29/58 | €10k | €7k | €15k | €14k |
| Amounts receivable within one year | 40/41 | €1k | €1k | €2k | €2k |
| Cash & bank | 54/58 | €6k | €5k | €12k | €11k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €13k | €11k | €21k | €21k |
| Equity | 10/15 | €12k | €9k | €15k | €13k |
| Contributions / capital | 10/11 | €2k | €2k | €2k | €2k |
| Accumulated profits (losses) | 14 | €10k | €7k | €13k | €11k |
| Amounts payable | 17/49 | €693 | €3k | €6k | €8k |
| Amounts payable within one year | 42/48 | €693 | €3k | €6k | €8k |
| Trade debts payable within one year | 44 | €131 | €2k | €789 | €726 |
| Income statement | |||||
| Gross operating margin | 9900 | €8k | €-3k | €7k | €16k |
| Operating result | 9901 | €4k | €-6k | €4k | €14k |
| Financial income | 75 | €80 | - | - | - |
| Financial charges | 65 | €48 | €44 | €59 | €35 |
| Result before taxes | 9903 | €4k | €-6k | €4k | €14k |
| Income taxes | 67/77 | €462 | €-36 | €1k | €3k |
| Net result for the period | 9904 | €4k | €-6k | €2k | €11k |
| Result to be appropriated | 9905 | €4k | €-6k | €2k | €11k |
Legal Structure
| NACE primary | - |
| Legal form | Private limited company(610) |
| Incorporation | 28-12-2021 |
| Status | Active |
| Postal code | 1081 |
Establishment units
MC4 THERAPY
since 20212.326.223.415
Real-estate footprint
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21492B0242/00G008 | Brussels | 106 m² | 1 · 74 m² | 12.4 m · 3 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
20-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Back to profitnet €4k
Net result €4k after one loss-making year.
31-12
Financial
Liquidity times 6current ratio 15.00
Current ratio from 2.45 to 15.00; short-term debt falls from €3k to €693.
25-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Weakest financial yearnet €-6k ▼366%
Net result drops to €-6k, the lowest in the series; recovery starts the following year.
30-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
24-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Physiotherapy86951
Names & trade names
| Legal nameFR | MC4 THERAPY |